Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. / Stougaard, Elisabeth B.; Kristensen, Peter L.; Kielgast, Urd; Andersen, Henrik U.; Hamid, Yasmin; Gæde, Peter H.; Søndergaard, Esben; Dørflinger, Gry H.; Fjeldborg, Karen K.; Hansen, Klavs W.; Thomsen, Henrik H.; Al-Imar, Thuraya M.J.; Røder, Michael; Sridhar, Vikas S.; Cherney, David; Rossing, Peter; Persson, Frederik.

I: Diabetes & vascular disease research, Bind 19, Nr. 5, 2022, s. 14791641221130043.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Stougaard, EB, Kristensen, PL, Kielgast, U, Andersen, HU, Hamid, Y, Gæde, PH, Søndergaard, E, Dørflinger, GH, Fjeldborg, KK, Hansen, KW, Thomsen, HH, Al-Imar, TMJ, Røder, M, Sridhar, VS, Cherney, D, Rossing, P & Persson, F 2022, 'Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis', Diabetes & vascular disease research, bind 19, nr. 5, s. 14791641221130043. https://doi.org/10.1177/14791641221130043

APA

Stougaard, E. B., Kristensen, P. L., Kielgast, U., Andersen, H. U., Hamid, Y., Gæde, P. H., Søndergaard, E., Dørflinger, G. H., Fjeldborg, K. K., Hansen, K. W., Thomsen, H. H., Al-Imar, T. M. J., Røder, M., Sridhar, V. S., Cherney, D., Rossing, P., & Persson, F. (2022). Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. Diabetes & vascular disease research, 19(5), 14791641221130043. https://doi.org/10.1177/14791641221130043

Vancouver

Stougaard EB, Kristensen PL, Kielgast U, Andersen HU, Hamid Y, Gæde PH o.a. Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. Diabetes & vascular disease research. 2022;19(5):14791641221130043. https://doi.org/10.1177/14791641221130043

Author

Stougaard, Elisabeth B. ; Kristensen, Peter L. ; Kielgast, Urd ; Andersen, Henrik U. ; Hamid, Yasmin ; Gæde, Peter H. ; Søndergaard, Esben ; Dørflinger, Gry H. ; Fjeldborg, Karen K. ; Hansen, Klavs W. ; Thomsen, Henrik H. ; Al-Imar, Thuraya M.J. ; Røder, Michael ; Sridhar, Vikas S. ; Cherney, David ; Rossing, Peter ; Persson, Frederik. / Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis. I: Diabetes & vascular disease research. 2022 ; Bind 19, Nr. 5. s. 14791641221130043.

Bibtex

@article{86cd3f43323b4c23b646bea0149f1a0b,
title = "Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis",
abstract = "BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark. METHODS: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate. RESULTS: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%. CONCLUSION: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.",
keywords = "diabetic ketoacidosis, sglt2 inhibitors, Type 1 diabetes",
author = "Stougaard, {Elisabeth B.} and Kristensen, {Peter L.} and Urd Kielgast and Andersen, {Henrik U.} and Yasmin Hamid and G{\ae}de, {Peter H.} and Esben S{\o}ndergaard and D{\o}rflinger, {Gry H.} and Fjeldborg, {Karen K.} and Hansen, {Klavs W.} and Thomsen, {Henrik H.} and Al-Imar, {Thuraya M.J.} and Michael R{\o}der and Sridhar, {Vikas S.} and David Cherney and Peter Rossing and Frederik Persson",
year = "2022",
doi = "10.1177/14791641221130043",
language = "English",
volume = "19",
pages = "14791641221130043",
journal = "Diabetes and Vascular Disease Research",
issn = "1479-1641",
publisher = "SAGE Publications",
number = "5",

}

RIS

TY - JOUR

T1 - Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis

AU - Stougaard, Elisabeth B.

AU - Kristensen, Peter L.

AU - Kielgast, Urd

AU - Andersen, Henrik U.

AU - Hamid, Yasmin

AU - Gæde, Peter H.

AU - Søndergaard, Esben

AU - Dørflinger, Gry H.

AU - Fjeldborg, Karen K.

AU - Hansen, Klavs W.

AU - Thomsen, Henrik H.

AU - Al-Imar, Thuraya M.J.

AU - Røder, Michael

AU - Sridhar, Vikas S.

AU - Cherney, David

AU - Rossing, Peter

AU - Persson, Frederik

PY - 2022

Y1 - 2022

N2 - BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark. METHODS: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate. RESULTS: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%. CONCLUSION: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.

AB - BACKGROUND: The indication for treatment of type 1 diabetes(T1D) with the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incidence of DKA in people with T1D treated with SGLT2i in Denmark. METHODS: Clinical data from adults with T1D in Denmark were collected from nine outpatient clinics. Electronic health records made the search for DKA accurate. RESULTS: From a population of 10.500 we observed 134 people treated with SGLT2i over a total period of 222 patient-years. Of those 72% were female, mean age (SD) was 51.4 (13.6) years and median duration of treatment (median, IQR) with an SGLT2i were 12.0 (6.0-29.0) months. The incidence of DKA was zero%. CONCLUSION: In 134 people with T1D treated with SGLT2i we found that none of the participants developed DKA during the treatment.

KW - diabetic ketoacidosis

KW - sglt2 inhibitors

KW - Type 1 diabetes

U2 - 10.1177/14791641221130043

DO - 10.1177/14791641221130043

M3 - Journal article

C2 - 36262089

AN - SCOPUS:85140415212

VL - 19

SP - 14791641221130043

JO - Diabetes and Vascular Disease Research

JF - Diabetes and Vascular Disease Research

SN - 1479-1641

IS - 5

ER -

ID: 323997300